Pembrolizumab Extends Survival in Patients With Leptomeningeal Carcinomatosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Single-Arm, Open-Label Phase 2 Trial of Pembrolizumab in Patients With Leptomeningeal Carcinomatosis
Nat. Med. 2020 Jun 02;[EPub Ahead of Print], PK Brastianos, EQ Lee, JV Cohen, SM Tolaney, NU Lin, N Wang, U Chukwueke, MD White, N Nayyar, A Kim, C Alvarez-Breckenridge, I Krop, MK Mahar, MS Bertalan, B Shaw, JL Mora, N Goss, M Subramanian, L Nayak, J Dietrich, DA Forst, BV Nahed, TT Batchelor, HA Shih, ER Gerstner, B Moy, D Lawrence, A Giobbie-Hurder, SL Carter, K Oh, DP Cahill, RJ SullivanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.